Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Vor Biopharma ( (VOR) ) just unveiled an update.
On July 9, 2025, Vor Biopharma appointed Sandesh Mahatme as Chief Financial Officer and Chief Business Officer, bringing over 30 years of experience in the biopharmaceutical industry. His appointment is expected to support the company’s transformation and growth in autoimmune disease treatment, particularly as it advances telitacicept through global Phase 3 development. Mahatme’s extensive background in strategic finance and capital formation is seen as instrumental in enhancing Vor Bio’s operations and shareholder value.
The most recent analyst rating on (VOR) stock is a Hold with a $0.40 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
Spark’s Take on VOR Stock
According to Spark, TipRanks’ AI Analyst, VOR is a Underperform.
Vor Biopharma faces significant financial challenges, with no revenue and ongoing losses. Technical indicators suggest weak market sentiment, and the lack of positive valuation metrics further underscores the risk. Investors should be cautious due to the high financial risk and uncertainty.
To see Spark’s full report on VOR stock, click here.
More about Vor Biopharma
Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases. The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide.
Average Trading Volume: 16,771,971
Technical Sentiment Signal: Buy
Current Market Cap: $299.9M
For an in-depth examination of VOR stock, go to TipRanks’ Overview page.